Applied Therapeutics, Inc. announced successful completion of a recent pre-New Drug Application (?NDA?) meeting with the Food and Drug Administration (FDA) regarding its govorestat (AT-007) Galactosemia program. Based on discussions with the FDA, the Company believes they are aligned with the FDA and plans to submit an NDA for govorestat (AT-007) for the treatment of Galactosemia in the fourth quarter of this year.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.115 USD | +9.53% | +18.57% | +51.49% |
05-09 | Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.49% | 534M | |
+19.04% | 125B | |
+14.01% | 108B | |
-7.57% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.80% | 16.37B | |
+2.53% | 13.58B | |
+27.96% | 11.66B |
- Stock Market
- Equities
- APLT Stock
- News Applied Therapeutics, Inc.
- Applied Therapeutics, Inc. Announces Successful Pre-Nda Meeting with the Fda and Confirms Plans to Submit Nda for Govorestat (At-007) for Treatment of Classic Galactosemia to Fda in Fourth Quarter 2023